EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression
VILLANOVA, Pa. and OAKLAND, Calif., Nov. 21, 2022 /PRNewswire/ -- EmbarkNeuro, a neuroscience-focused biotech firm previously referred to as Ancora ...